Defense World
13 Dec 2025, 08:58 UTC · 48w ago
Alkeon Capital Management LLC Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
Impact · against what's priced in
Alkeon Capital Management's 20.8% reduction in BioCryst Pharmaceuticals suggests a cautious outlook or portfolio rebalancing by a major holder. While the investor retains a significant position, the sale of 1.5 million shares creates minor negative pressure on institutional sentiment.
- BCRX−0.20
No priced-in read yet





